



## **BioXcel to Showcase PharmGPS™ Oncology and Immuno-Oncology Suite at Two Prominent Industry Conferences**

March 24, 2015

Presentations to highlight a big data approach for deciphering the applications of immune checkpoint inhibitors and the potential array of therapeutics

BRANFORD, Conn., March 24, 2015 /PRNewswire/ -- BioXcel Corporation, a global leader in providing cloud-based Pharma big data solutions for discovering novel products, today announced that Dr. Krishnan Nandabalan, Ph.D., President and Chief Scientific Officer, will present the capabilities of the Company's PharmGPS™ Oncology and Immuno-Oncology Suite at two upcoming industry conferences.

Dr. Nandabalan will present an overview of PharmGPS™ - the company's proprietary, big data-powered analytics and discovery platform, and join a group of industry and academic leaders in a [roundtable discussion](#) entitled '**Immuno-Oncology: The Future**' during Phacilitate's Oncology Leaders' Forum, taking place March 24-26 in Boston, MA. The panel will focus on a variety of prevalent topics in oncology, including emerging immune checkpoint targets, the application of checkpoint inhibitor biology to other therapeutic areas and indications and the future of disruptive immunotherapeutic technologies in the cancer space.

Additionally, Dr. Nandabalan will present an abstract on '**Targeting Immune Checkpoints: Using a Big Data Approach**' at the upcoming [AACR Annual Meeting in April, 2015](#). Dr. Nandabalan will provide a unique perspective on big data applications to chart the impact of immuno-oncological therapeutic approaches across solid and hematological tumors using PharmGPS™. Dr. Nandabalan will present the poster during the session on Computational Tools / Genomic Profiling of Tumors on Sunday, April 19, 2015 from 1:00 – 5:00 p.m. EDT.

### **About PharmGPS™ Oncology and Immuno-Oncology Suite**

A live and multi-dimensional platform, BioXcel's proprietary suite enables the extensive analysis of solid tumors and hematological malignancies, and the impact of constituent global drug pipelines and benchmarking, novel drug targets and therapeutic approaches, including the inhibition of immune checkpoints, on standards of care and lines of therapies. All Key drivers necessary for designing the most optimal combination therapies, clinical trial design and positioning of the right anti cancer agents are taken into account to maximize market share and most importantly benefit to the patient. Furthermore, the suite is comprehensive in assessing all modalities, combinations of therapies and different stages of development. This extensive analysis delineates an optimal path with respect to indication segment relevance, best-fit therapies, and target effectiveness compared to the most relevant standard of care.

### **About BioXcel**

BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS™ - a live analytics platform; an Integrated Center of Excellence housing multidisciplinary scientific, commercial and medical teams; and an executive team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.

### **Contact:**

BioXcel Corporation  
Anita Ganjoo  
Corporate Communications  
Email: [aganjoo@bioxcel.com](mailto:aganjoo@bioxcel.com)  
Tel: 203 273 8388

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/bioxcel-to-showcase-pharmgps-oncology-and-immuno-oncology-suite-at-two-prominent-industry-conferences-300054932.html>

SOURCE BioXcel Corporation